Accessibility Menu
 
Lexicon Pharmaceuticals logo

Lexicon Pharmaceuticals

(NASDAQ) LXRX

Current Price$1.56
Market Cap$660.94M
Since IPO (2000)-99%
5 Year-77%
1 Year+352%
1 Month+18%

Lexicon Pharmaceuticals Financials at a Glance

Market Cap

$660.94M

Revenue (TTM)

$49.80M

Net Income (TTM)

$50.34M

EPS (TTM)

$-0.14

P/E Ratio

-11.24

Dividend

$0.00

Beta (Volatility)

1.59 (High)

Price

$1.56

Volume

222,550

Open

$1.59

Previous Close

$1.56

Daily Range

$1.52 - $1.59

52-Week Range

$0.32 - $1.83

LXRX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lexicon Pharmaceuticals

Industry

Pharmaceuticals

Employees

81

CEO

Michael Exton, PhD

Headquarters

The Woodlands, TX 77381, US

LXRX Financials

Key Financial Metrics (TTM)

Gross Margin

99%

Operating Margin

-98%

Net Income Margin

-1%

Return on Equity

-40%

Return on Capital

-30%

Return on Assets

-27%

Earnings Yield

-8.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$660.94M

Shares Outstanding

423.68M

Volume

222.55K

Short Interest

0.00%

Avg. Volume

2.81M

Financials (TTM)

Gross Profit

$49.53M

Operating Income

$48.91M

EBITDA

$48.29M

Operating Cash Flow

$67.85M

Capital Expenditure

$0.00

Free Cash Flow

$67.85M

Cash & ST Invst.

$96.23M

Total Debt

$62.24M

Lexicon Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$5.49M

-79.3%

Gross Profit

$5.17M

+733.2%

Gross Margin

94.19%

N/A

Market Cap

$660.94M

N/A

Market Cap/Employee

$6.42M

N/A

Employees

103

N/A

Net Income

$15.53M

+54.0%

EBITDA

$14.66M

+27.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$33.99M

-73.8%

Accounts Receivable

$2.38M

-31.4%

Inventory

$281.00K

+21.6%

Long Term Debt

$56.00M

-47.8%

Short Term Debt

$6.24M

+430.8%

Return on Assets

-27.21%

N/A

Return on Invested Capital

-29.80%

N/A

Free Cash Flow

$17.23M

+21.5%

Operating Cash Flow

$17.23M

+19.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCGNOcugen, Inc.
$2.04-8.93%
CMPXCompass Therapeutics, Inc.
$5.15-4.45%
OMEROmeros Corporation
$11.00-1.08%
ADCTADC Therapeutics S.A.
$3.86-4.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
TAT&T
$28.31+0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About LXRX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.